Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics (Nasdaq: ABEO) has announced the granting of equity awards to five new non-executive employees. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) on February 28, 2025, consist of an aggregate of 16,300 restricted shares of Abeona common stock.
The restricted stock awards feature a three-year vesting schedule, with one-third of the shares vesting annually on each anniversary of the Grant Date. Full vesting will occur on the third anniversary, contingent upon continued employment with Abeona.
Abeona Therapeutics (Nasdaq: ABEO) ha annunciato l'assegnazione di premi azionari a cinque nuovi dipendenti non esecutivi. I premi, approvati dal Comitato per la Compensazione ai sensi della Regola di Quotazione Nasdaq 5635(c)(4) il 28 febbraio 2025, consistono in un totale di 16.300 azioni riservate di azioni ordinarie di Abeona.
Le assegnazioni di azioni riservate prevedono un programma di maturazione di tre anni, con un terzo delle azioni che matura annualmente in corrispondenza di ogni anniversario della Data di Assegnazione. La maturazione completa avverrà al terzo anniversario, a condizione di un'occupazione continuativa con Abeona.
Abeona Therapeutics (Nasdaq: ABEO) ha anunciado la concesión de premios en acciones a cinco nuevos empleados no ejecutivos. Los premios, aprobados por el Comité de Compensación bajo la Regla de Cotización Nasdaq 5635(c)(4) el 28 de febrero de 2025, consisten en un total de 16,300 acciones restringidas de acciones ordinarias de Abeona.
Los premios de acciones restringidas cuentan con un programa de adquisición de tres años, donde un tercio de las acciones se adquiere anualmente en cada aniversario de la Fecha de Concesión. La adquisición completa ocurrirá en el tercer aniversario, sujeto a la continuación del empleo con Abeona.
Abeona Therapeutics (Nasdaq: ABEO)는 다섯 명의 새로운 비상임 직원에게 주식 보상을 부여했다고 발표했습니다. 이 보상은 2025년 2월 28일 Nasdaq 상장 규정 5635(c)(4)에 따라 보상위원회에서 승인되었으며, 총 16,300주의 제한 주식으로 구성됩니다.
제한 주식 보상은 3년의 베스팅 일정을 특징으로 하며, 주식의 3분의 1이 부여일의 매년 기념일에 베스팅됩니다. 전체 베스팅은 세 번째 기념일에 발생하며, Abeona와의 지속적인 고용에 따라 달라집니다.
Abeona Therapeutics (Nasdaq: ABEO) a annoncé l'octroi de récompenses en actions à cinq nouveaux employés non exécutifs. Les récompenses, approuvées par le Comité de Rémunération conformément à la Règle d'Inscription Nasdaq 5635(c)(4) le 28 février 2025, consistent en un total de 16 300 actions restreintes des actions ordinaires d'Abeona.
Les récompenses en actions restreintes comprennent un calendrier d'acquisition de trois ans, avec un tiers des actions qui s'acquiert annuellement à chaque anniversaire de la Date d'Octroi. L'acquisition complète aura lieu à la troisième année, sous réserve d'un emploi continu avec Abeona.
Abeona Therapeutics (Nasdaq: ABEO) hat die Gewährung von Aktienoptionen an fünf neue nicht-executive Mitarbeiter bekannt gegeben. Die Optionen, die am 28. Februar 2025 vom Vergütungsausschuss gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt wurden, bestehen aus insgesamt 16.300 eingeschränkten Aktien des Stammkapitals von Abeona.
Die eingeschränkten Aktienoptionen sehen einen Drei-Jahres-Vesting-Plan vor, bei dem ein Drittel der Aktien jährlich an jedem Jahrestag des Gewährungsdatums vestet. Die vollständige Vesting erfolgt am dritten Jahrestag, abhängig von der fortgesetzten Beschäftigung bei Abeona.
- None.
- None.
CLEVELAND, March 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On February 28, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 16,300 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and outcome of the FDA’s review of our BLA resubmission for pz-cel; the FDA’s grant of a Priority Review Voucher upon pz-cel approval; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
FAQ
How many restricted shares did Abeona Therapeutics (ABEO) grant in their February 2025 inducement awards?
What is the vesting schedule for ABEO's February 2025 employee inducement grants?
Under which Nasdaq rule were ABEO's February 2025 inducement grants approved?
How many new employees received ABEO's February 2025 inducement grants?
